Company
Orphalan
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
1
1 still marketed
Novel approvals
0
Approvals since 2021
1
Originals and new uses
Phase 3 trials
2
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Cuvrior approved OrphanApr 28, 2022
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
- Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.Pivotal-lookingRecruiting
OrphalanIndustry
NCT07465718 · 38 participants (planned) · Start Sep 3, 2026 · Primary completion Feb 2028
Drug: TETA 4HCl formulation; D-Penicillamine · For: Wilson's Disease
Sites: Denver, Colorado; New Haven, Connecticut; Ann Arbor, Michigan · 10 sites in all
Marketed drugs (1)
Newest FDA action first.
- Cuvrior Trientine Tetrahydrochloride · 2022
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.